Rasidone 40 mg and 120 mg proteasome inhibitor were superior to placebo on the p arm and the CGI BPRSd 80 mg were also superior to placebo scores lurasidone BPRSd S and CGI. In the placebo-controlled arm The controller EEA and active, 40 mg and 120 mg were superior to placebo and olanzapine lurasidone on the PANSS and CGI-S In the last part of the study, three fixed doses were superior to placebo show with only 80 mg / day dose compared to placebo. As can be seen, the data show pr Presents arguments and evidence, when coupled with the FDA approval, these new antipsychotics should be taken at least s R and m for may have more effectively. However, there are some known problems with this drug class. As warnings of psychosis in dementia, stroke, neuroleptic malignant syndrome, tardive dyskinesia, metabolic syndrome, Hyperprolaktin Chemistry and other side effects are still listed in the instructions is the prescribing Doctors and nurses with these other atypical antipsychotics should be familiar with these problems. The execution ll Of the evidence base NonpsychiatricMedications rofecoxib. Imposed by the juxtaposition of the relatively short clinical trials of these agents with the life sentence of schizophrenia in most patients, it is fair, a few drugs that have that have won look as evidence-based, only to find that not all reaches of the evidence in clinical trials . For example, FDA approved rofecoxib onMay 20, 1999. There was a selective cyclooxygenase-2 nonsteroidal anti-inflammatory stero Tue intended for the treatment of symptoms of osteoarthritis, acute pain management to treat adults and symptom my menstruation. Clinical studies have controlled both The placebo and active control, for a period of 6 weeks to 86 weeks. Controlled Assets included in clinical trials of ibuprofen 800 mg three times t T was like three times Possible and diclofenac 50 mg three times t Resembled controls in Arm.Active theOA in analgesia and dysmenorrhea arms included naproxen 550 mg and 400 mg of ibuprofen. The FDA announced in September 30 June 2004 that merck & Co., Inc. voluntarily withdrew rofecoxib from the U.S. market. The well-known reasons for withdrawal include increased Hten risks kardiovaskul Re Including events Lich myocardial infarction and stroke acutemyocardial, and the development of polyps c Lon recurring. These symptoms were observed in patients taking the drug occurred for more than 18 months. Tegaserod. Tegaserod has been approved by the FDA, 24 July 2002. It was used to the syndrome of c Lon treat irritable younger with constipation and chronic idiopathic constipation in women over 55 years. Tegaserod clinical trials consisted of 12 weeks placebo controlled EAA double-blind study. No validated measurement instrument of the check was found, however, the measurement was obtained by subjective questionnaires. The question was asked to please consider t, in particular your overall well and symptoms of abdominal pain, pain, and his habits, how you felt last week in relation to your IBS Ver Changed intestine. Compared to the fa If you felt as a rule, before entering the study E7080 howwould you rate your relief of symptoms in the last week Five categories of responses were identified: completely relieved ndig, significantly relieved, somewhat relieved, unchanged, or worse. Efficacy was not noted Beyo.